Dr. Gavin M. Bendle is the Vice President, Research and Development at Neogene Therapeutics. He has been actively engaged in the field of adoptive T cell therapy of cancer for over 17 years and has co-authored numerous publications on this subject. Before joining Neogene, Dr. Bendle was a Senior Director of Cell Therapy at Kite Pharma, where he served as Kite EU Research Site Head. Prior to that, he was a Principal Investigator and Leukemia & Lymphoma Research Bennett Senior Fellow at the University of Birmingham in the United Kingdom, where his group focused on the engineering of T cell immunity to cancer.
Dr. Bendle was a Leukemia and Lymphoma Research Postdoctoral Fellow in the laboratory of Professor Ton N.M. Schumacher at the Netherlands Cancer Institute. He received his Ph.D. in Tumor Immunology from Imperial College London in the laboratory of Professor Hans Stauss. Dr. Bendle also earned his M.Sc. in Immunology from Imperial College London, and a B.Sc. in Zoology from the University of Sheffield in the United Kingdom.